SLU-PP-322

SLU-PP-332 is a synthetic, orally active small molecule . It targets all three estrogen-related receptor isoforms: ERRα, ERRβ, and ERRγ . The compound shows slightly higher potency for ERRα, with an EC₅₀ of 98 nM in cell-based assays . Importantly, researchers developed it using a rational drug design approach . It is not a peptide, despite some online marketing claims .

2. Mechanism of Action

SLU-PP-332 binds to and activates the estrogen-related receptors . This activation leads to the recruitment of coactivators such as PGC-1α. Consequently, it upregulates target genes involved in fatty acid metabolism and mitochondrial function . For example, it increases the expression of Pyruvate Dehydrogenase Kinase 4 (Pdk4), a critical regulator of glucose utilization . This shift in metabolism promotes fatty acid oxidation over glucose use . Furthermore, ERR agonism transcriptionally activates a broad spectrum of metabolic genes .

[Image Placeholder: Chart showing EC₅₀ values for ERRα, ERRβ, and ERRγ]
Alt text: SLU-PP-332 potency data for ERRα, ERRβ, and ERRγ receptor activation

3. Preclinical Research Findings

Animal studies demonstrate promising metabolic effects. In diet-induced obese mice, SLU-PP-332 decreased body weight and fat mass . It also improved glucose tolerance and insulin sensitivity in metabolic syndrome models . Moreover, the compound increased running endurance and oxidative muscle fibers in healthy mice . In heart failure models, it improved ejection fraction, reduced fibrosis, and increased survival . Additionally, recent research suggests it may restore mitochondrial function and reduce inflammation in aging kidneys . However, all published research comes from preclinical animal models.

4. Metabolism and Doping Status

A 2026 study identified 22 metabolites of SLU-PP-332 using human liver S9 fractions . These metabolites may be useful for doping-control purposes . The World Anti-Doping Agency (WADA) prohibits exercise mimetics and metabolic modulators in sports . Therefore, SLU-PP-332 is a banned substance for competitive athletes .

5. Regulatory and Safety Status

No human clinical trials have been completed for SLU-PP-332 . It has no FDA approval for any indication. It is a research compound only . Unregulated online vendors sell “research-grade” SLU-PP-332, but these products lack pharmaceutical-grade manufacturing standards . For more on research compound safety, review our Research Compound Safety Guide. Externally, refer to the FDA guidelines on investigational drugs and the PubMed research repository for peer-reviewed literature.

6. Conclusion

SLU-PP-332 is a promising research tool for studying ERR-mediated metabolic pathways. Its exercise-mimetic effects in animal models are well-documented. Nevertheless, the complete absence of human data means it remains strictly for laboratory use. Researchers should interpret findings cautiously and prioritize safety.